Linked Life Data

15820913

Source:http://linkedlifedata.com/resource/pubmed/id/15820913

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-4-11
pubmed:abstractText
This was a 6-week, randomized, double-blind, multicenter study evaluating the efficacy of pregabalin in the treatment of painful diabetic neuropathy. Two hundred forty-six men and women with painful diabetic neuropathy received pregabalin (150 or 600 mg/day by mouth) or placebo. The primary efficacy variable was mean pain score at the end of treatment. Efficacy results indicate that pregabalin 600 mg/day significantly decreased mean pain score to 4.3 (vs 5.6 for placebo, P = .0002) and increased the proportion of patients who had a > or =50% decrease from baseline pain (39% vs 15% for placebo, P = .002). Pregabalin also significantly reduced sleep interference, past week and present pain intensity, sensory and affective pain scores, and bodily pain and decreased by > or =50% the number of patients describing their pain as gnawing, sickening, fearful, and punishing-cruel. More patients receiving pregabalin 600 mg/day than placebo showed improvement, as rated on the Clinical and Patient Global Impression of Change scales, 73% vs 45% and 85% vs 47%, respectively. Pregabalin 150 mg/day was essentially no different from placebo. Dizziness was the most common side effect. These study results show pregabalin 600 mg/day to be safe and effective in reducing the pain and other associated symptoms of painful diabetic neuropathy. PERSPECTIVE: Painful diabetic peripheral neuropathy is a challenging neuropathic pain syndrome. This randomized controlled trial demonstrates that pregabalin, a new drug that interacts with the alpha2-delta protein subunit of the voltage-gated calcium channel, is an efficacious and safe treatment for the pain of this condition.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1526-5900
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
253-60
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15820913-Aged, pubmed-meshheading:15820913-Analgesia, pubmed-meshheading:15820913-Analgesics, pubmed-meshheading:15820913-Anticonvulsants, pubmed-meshheading:15820913-Calcium Channel Blockers, pubmed-meshheading:15820913-Calcium Channels, pubmed-meshheading:15820913-Diabetic Neuropathies, pubmed-meshheading:15820913-Dizziness, pubmed-meshheading:15820913-Double-Blind Method, pubmed-meshheading:15820913-Female, pubmed-meshheading:15820913-Humans, pubmed-meshheading:15820913-Male, pubmed-meshheading:15820913-Middle Aged, pubmed-meshheading:15820913-Pain Measurement, pubmed-meshheading:15820913-Placebo Effect, pubmed-meshheading:15820913-Placebos, pubmed-meshheading:15820913-Sleep Initiation and Maintenance Disorders, pubmed-meshheading:15820913-Stress, Psychological, pubmed-meshheading:15820913-Treatment Outcome, pubmed-meshheading:15820913-gamma-Aminobutyric Acid
pubmed:year
2005
pubmed:articleTitle
Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial.
pubmed:affiliation
Neurology Department, St John Medical Center, Tulsa, Oklahoma, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study